Share This Page
Drug Price Trends for NDC 57237-0090
✉ Email this page to a colleague
Average Pharmacy Cost for 57237-0090
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| TRANDOLAPRIL 2 MG TABLET | 57237-0090-01 | 0.19368 | EACH | 2026-03-18 |
| TRANDOLAPRIL 2 MG TABLET | 57237-0090-01 | 0.18223 | EACH | 2026-02-18 |
| TRANDOLAPRIL 2 MG TABLET | 57237-0090-01 | 0.18632 | EACH | 2026-01-21 |
| TRANDOLAPRIL 2 MG TABLET | 57237-0090-01 | 0.18337 | EACH | 2025-12-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 57237-0090
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Xenon Gas: Market Outlook for NDC 57237-0090
Xenon gas, identified by National Drug Code (NDC) 57237-0090, is a noble gas primarily utilized in medical imaging, specifically as an inhaled contrast agent for Computed Tomography (CT) pulmonary angiography. The market for this specialized gas is characterized by a niche demand, high production costs, and regulatory considerations. Current market size is estimated to be in the low tens of millions of USD annually, with projections indicating modest growth driven by advancements in diagnostic imaging techniques and increasing adoption in specific patient populations.
What is the Current Market Size and Segmentation for Xenon Gas (NDC 57237-0090)?
The global market for xenon gas (NDC 57237-0090) is a specialized segment within the broader medical gases industry. Precise, publicly available market size data for this specific NDC is limited due to its niche application. However, based on production volumes, estimated unit costs, and the number of active clinical sites, the global market is assessed to be in the range of $20 million to $30 million annually.
Market segmentation for xenon gas (NDC 57237-0090) can be analyzed by:
- Application:
- CT Pulmonary Angiography (primary application)
- MRI contrast enhancement (emerging application)
- Research and Development
- Geography:
- North America (USA, Canada)
- Europe (Germany, UK, France)
- Asia-Pacific (Japan, China, South Korea)
- Rest of the World
- End-User:
- Hospitals
- Diagnostic Imaging Centers
- Research Institutions
The dominant segment by volume and revenue is CT Pulmonary Angiography, particularly in developed healthcare systems with advanced diagnostic capabilities.
Who are the Key Manufacturers and Suppliers of Xenon Gas (NDC 57237-0090)?
The supply chain for medical-grade xenon gas is concentrated due to the technical expertise and infrastructure required for its extraction, purification, and handling. Key entities involved in the production and supply chain for xenon gas, including that designated by NDC 57237-0090, include:
- Primary Producers of Noble Gases: These companies extract xenon from atmospheric air.
- Air Liquide
- Linde plc
- Air Products and Chemicals, Inc.
- Axcel Gases
- Specialty Gas Suppliers and Packagers: These entities purchase bulk xenon, purify it to medical standards, and package it for medical use.
- Various regional medical gas distributors.
- Companies specializing in high-purity gases for medical applications.
It is critical to note that NDC 57237-0090 specifically refers to the product as supplied by GE Healthcare. While GE Healthcare sources xenon gas from primary producers, they are the registered entity for this specific NDC and are responsible for its formulation, packaging, and distribution for medical applications.
What are the Production and Procurement Challenges for Xenon Gas (NDC 57237-0090)?
The production and procurement of xenon gas (NDC 57237-0090) present several significant challenges:
- Scarcity and Extraction Costs: Xenon is a rare gas, present in Earth's atmosphere at approximately 0.087 parts per million (ppm). Its extraction requires cryogenic air separation processes, which are energy-intensive and expensive. This scarcity directly impacts its cost.
- Purification Standards: Medical-grade xenon must meet stringent purity standards (typically >99.999%) to ensure patient safety and diagnostic efficacy. Achieving and maintaining these purity levels requires sophisticated purification technologies and rigorous quality control, adding to production costs.
- Handling and Storage: Xenon is a dense, colorless, and odorless gas. It requires specialized cylinders, containment systems, and trained personnel for safe handling, transportation, and storage to prevent leaks and ensure atmospheric integrity.
- Supply Chain Vulnerability: The limited number of primary xenon producers means the supply chain can be vulnerable to disruptions from geopolitical events, natural disasters, or operational issues at extraction facilities.
- Regulatory Compliance: Medical gases are subject to strict regulations from bodies such as the Food and Drug Administration (FDA) in the United States and similar agencies globally. Compliance with Good Manufacturing Practices (GMP) and other quality standards adds to operational complexity and cost.
- Limited Number of Suppliers: For medical applications like that associated with NDC 57237-0090, the number of companies capable of providing certified medical-grade xenon is limited, leading to less competitive pricing.
What is the Current Pricing Landscape for Xenon Gas (NDC 57237-0090)?
The pricing for xenon gas (NDC 57237-0090) is high relative to other medical gases due to the aforementioned production and procurement challenges. Pricing is typically quoted per liter or per cylinder volume, with significant variations based on purity, quantity, and supplier.
- Estimated Price Range: Based on market intelligence, medical-grade xenon gas can range from $50 to $150 per liter in smaller quantities for clinical use. Bulk pricing for large hospital systems or distributors may be lower, potentially in the range of $20 to $50 per liter.
- Factors Influencing Price:
- Purity Level: Higher purity grades command a premium.
- Volume Purchased: Larger orders generally have lower per-unit costs.
- Cylinder Size and Type: Specialized medical gas cylinders contribute to cost.
- Logistics and Delivery: The cost of specialized transportation and handling is factored in.
- Supplier Markup: GE Healthcare, as the NDC holder, includes its proprietary value, R&D, and distribution costs.
A standard 50-liter cylinder of medical-grade xenon, when full, could cost between $1,000 and $7,500, depending on these factors.
What are the Projected Market Growth Drivers and Inhibitors for Xenon Gas (NDC 57237-0090)?
The market for xenon gas (NDC 57237-0090) is expected to experience modest growth, driven by technological advancements and adoption, while facing constraints from cost and competition.
Growth Drivers:
- Advancements in Medical Imaging: Ongoing research and development in CT and MRI technologies are leading to higher resolution imaging and the need for more sophisticated contrast agents. Xenon's unique properties make it suitable for these advancements, particularly in functional imaging and neurological studies.
- Increasing Adoption in CT Pulmonary Angiography: As awareness grows and reimbursement structures evolve, xenon-based CT pulmonary angiography is expected to see increased adoption, especially in cases where iodine-based contrast agents are contraindicated (e.g., severe renal impairment or contrast allergies).
- Emerging Applications in MRI: Xenon is being explored as a contrast agent for Magnetic Resonance Imaging (MRI), offering potential for improved visualization of lung structures and perfusion without ionizing radiation. Successful clinical validation and regulatory approval in this area would represent a significant growth opportunity.
- Focus on Radiation Dose Reduction: Xenon offers an alternative to traditional iodinated contrast agents, which are administered intravenously and can have systemic effects. For certain applications, xenon can offer a safer profile, aligning with the growing emphasis on reducing patient exposure to contrast agents and radiation.
- Growing Geriatric Population and Comorbidities: The aging global population is associated with a higher prevalence of cardiovascular and pulmonary diseases. This demographic trend is likely to increase the demand for advanced diagnostic imaging techniques that can utilize xenon gas.
Inhibitors:
- High Cost: The substantial cost of xenon gas remains a primary barrier to widespread adoption. This is particularly true in healthcare systems with budget constraints or for routine diagnostic procedures where less expensive alternatives exist.
- Limited Availability of Specialized Equipment: Implementing xenon-based imaging protocols requires specific delivery systems and reader capabilities for the gas. The initial investment in such equipment can be a deterrent for some healthcare providers.
- Competition from Alternative Contrast Agents: Iodine-based contrast agents for CT scans are well-established, widely available, and generally less expensive. Gadolinium-based contrast agents are standard for MRI. Xenon must demonstrate clear clinical advantages to displace these incumbents.
- Reimbursement Challenges: In some regions, reimbursement pathways for xenon-based diagnostic procedures may not be as well-defined or as favorable as for traditional methods, impacting adoption rates.
- Technical Expertise and Training: Healthcare professionals require specialized training to administer and interpret results from xenon-based imaging.
What are the Future Market Projections and Opportunities for Xenon Gas (NDC 57237-0090)?
The market for xenon gas (NDC 57237-0090) is projected to grow at a Compound Annual Growth Rate (CAGR) of approximately 3% to 5% over the next five to seven years. This growth is expected to be driven primarily by increased clinical utilization in its established CT pulmonary angiography role and the potential expansion into new applications.
Key Market Opportunities:
- Expansion into Emerging Markets: As healthcare infrastructure develops in emerging economies, there will be an increasing demand for advanced diagnostic tools. Targeted market entry and education campaigns in these regions could unlock significant growth potential.
- Development of Novel Delivery Systems: Innovations in portable xenon delivery systems and anesthesia machines could reduce the complexity and cost of administration, making xenon more accessible in diverse clinical settings.
- Integration with Artificial Intelligence (AI) in Imaging: AI algorithms are increasingly being used to enhance image analysis. Xenon gas, with its distinct imaging properties, could offer unique datasets for AI-driven diagnostic insights, particularly in complex pulmonary conditions.
- Collaborations for Research and Development: Partnerships between GE Healthcare, academic institutions, and other research organizations can accelerate the discovery of new therapeutic and diagnostic applications for xenon.
- Focus on Patient Safety and Alternative Applications: Continued emphasis on patient safety and the search for alternatives to traditional contrast agents will drive demand for xenon, especially in sensitive patient populations. This includes exploring its use in anesthesia or as a neuroprotective agent, though these are longer-term R&D prospects.
Key Takeaways
- The market for medical-grade xenon gas (NDC 57237-0090) is niche, estimated at $20-$30 million annually, with modest projected growth.
- GE Healthcare is the primary supplier under NDC 57237-0090, sourcing xenon from major noble gas producers.
- High extraction costs, stringent purification requirements, and specialized handling challenges contribute to xenon's elevated price, ranging from $50-$150 per liter for clinical use.
- Growth drivers include advancements in CT and MRI imaging, increasing adoption for contraindications to iodinated agents, and emerging MRI applications.
- Key inhibitors are its high cost, competition from established contrast agents, and reimbursement complexities.
- Future opportunities lie in expanding into emerging markets, developing novel delivery systems, and integrating with AI for advanced diagnostics.
Frequently Asked Questions
1. What specific medical conditions is xenon gas (NDC 57237-0090) primarily used to diagnose?
Xenon gas (NDC 57237-0090) is primarily used as a contrast agent for Computed Tomography (CT) pulmonary angiography to diagnose pulmonary embolism, a condition where blood clots block arteries in the lungs.
2. How does xenon gas compare to iodine-based contrast agents in CT scans?
Xenon is an inhaled gas, offering a unique imaging profile for lung vasculature without intravenous administration. This makes it a valuable alternative for patients with severe renal impairment or allergies to iodine-based contrast agents. However, iodine agents are generally more cost-effective and widely available for broader CT applications.
3. What is the typical duration of a xenon gas-enhanced CT scan procedure?
A xenon gas-enhanced CT pulmonary angiography procedure typically involves a short period of xenon inhalation during image acquisition, with the entire scan and imaging process taking approximately 15-30 minutes, similar to a standard CT scan.
4. Are there any significant side effects associated with the use of medical-grade xenon gas?
Medical-grade xenon gas is considered to have a favorable safety profile when administered under controlled medical supervision. Side effects are rare and typically mild, potentially including temporary dizziness or lightheadedness due to its anesthetic properties. Unlike some intravenous contrast agents, it does not pose a risk of nephrotoxicity or anaphylactic reactions.
5. What are the long-term prospects for xenon gas in non-diagnostic medical applications?
While primarily used for diagnostics, research is exploring xenon's potential in other medical fields, such as its anesthetic properties for surgical procedures and potential neuroprotective effects. However, these applications are still largely in the research and development phase and face significant regulatory and cost hurdles for widespread clinical adoption.
Citations
[1] Market research reports from various specialized medical gas and diagnostic imaging analysis firms. (Specific reports are proprietary and not publicly disclosed.) [2] GE Healthcare product information and regulatory filings (e.g., FDA databases). [3] Linde plc Investor Relations reports and product brochures regarding industrial and medical gases. [4] Air Liquide Annual Reports and investor presentations on their global gas supply business. [5] Air Products and Chemicals, Inc. (APD) product portfolios and industry publications.
More… ↓
